Composition or method including (t)ew-7197 for treating or preventing corneal endothelial diseases

Abstract

The present disclosure provides a composition for treating or preventing symptoms, disorders, or diseases of the corneal endothelium. The present invention specifically provides a composition which is for treating or preventing symptoms, disorders, or diseases of the corneal endothelium, and includes (T)EW-7197 (N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), a derivative thereof, a pharmaceutically acceptable salt thereof, or a solvate of any of the foregoing.

The invention claimed is: 
     
       1. A method for treating or preventing a corneal endothelial condition, disorder, or disease, comprising administering to the subject an effective amount of (T)EW-7197 (N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), or a pharmaceutically acceptable salt thereof, or a solvate thereof. 
     
     
       2. The method of  claim 1 , wherein the method suppresses a reduction in a corneal endothelial cell density. 
     
     
       3. The method of  claim 1 , wherein the corneal endothelial condition, disorder, or disease is Fuchs' endothelial corneal dystrophy or corneal guttata. 
     
     
       4. The method of  claim 1 , wherein the corneal endothelial condition, disorder, or disease is due to overexpression of extracellular matrix (ECM). 
     
     
       5. The method of  claim 4 , wherein the extracellular matrix (ECM) is selected from the group consisting of type I collagen, type IV collage, type V collage, and fibronectin. 
     
     
       6. The method of  claim 4 , wherein the corneal endothelial condition, disorder, or disease is selected from the group consisting of Fuchs' endothelial corneal dystrophy, guttae formation, thickening of a Descemet's membrane, thickening of a cornea, corneal opacity, scar, corneal nebula, corneal macula, leukoma, glare, and blurred vision. 
     
     
       7. The method of  claim 1 , wherein the corneal endothelial condition, disorder, or disease is in Fuchs' endothelial corneal dystrophy. 
     
     
       8. The method of  claim 1 , wherein the (T)EW-7197, or a pharmaceutically acceptable salt thereof, or a solvate thereof is administered at a concentration of about 0.001 mM to about 10 mM. 
     
     
       9. The method of  claim 1 , wherein the (T)EW-7197, or a pharmaceutically acceptable salt thereof, or a solvate thereof is administered at a concentration of about 0.01 mM to about 5 mM. 
     
     
       10. The method of  claim 1 , wherein the (T)EW-7197, or a pharmaceutically acceptable salt thereof, or a solvate thereof is administered as an eye drop.